According to the research results in recent years, the current new hepatitis B drugs include Tenofovir Propofol Fumarate and Emtinofovir. The therapeutic effect, drug resistance rate and side effects will be further improved than the original drugs. These new drugs have a stronger antiviral effect, and if taken orally for a long period of time, they can control the hepatitis B virus more effectively. The therapeutic effect has been improved. At the same time, the resistance rate of the new drugs is lower, after the purpose of clinical data, compared with lamivudine, tibivudine, adefovir and other drugs resistance rate is reduced. In addition, the incidence of clinical side effects, such as damage to kidney function, is lower than before, and the incidence of hepatocellular carcinoma and cirrhosis is reduced after treatment. The treatment and selection of new hepatitis B drugs should still be used under the guidance of a professional hepatologist.